We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Targeted RNA-Sequencing Panel Detects Gene Fusions in Solid Tumors

By LabMedica International staff writers
Posted on 07 Dec 2021
Print article
Image: The TruSight RNA Fusion Panel kit provides comprehensive gene fusion detection in formalin-fixed, paraffin-embedded (FFPE) and other cancer samples (Photo courtesy of Illumina)
Image: The TruSight RNA Fusion Panel kit provides comprehensive gene fusion detection in formalin-fixed, paraffin-embedded (FFPE) and other cancer samples (Photo courtesy of Illumina)
Increasingly, rearrangements resulting in gene fusions have been revealed in multiple tumor types across diverse organ systems. These gene fusions can drive tumorigenesis by altering gene expression and activity. Timely and reliable detection of fusions provides useful information to the pathologist and clinical team.

Molecular techniques, such as fluorescence in situ hybridization (FISH), reverse transcription PCR (RT-PCR), and Sanger and next-generation sequencing (NGS), have enabled discovery of characteristic fusions associated with particular tumors. With FISH and RT-PCR, the genes involved must be known or suspected, and usually only a few prioritized assays are run, due to cost and time limitations. These methods are not suitable for the identification of novel fusion partners.

Clinical Scientists at the Washington University School of Medicine (St. Louis, MO, USA) included 153 sarcoma and carcinoma cases submitted for FISH, RT-PCR, or DNA-based NGS testing during diagnostic workup between 2013 and 2019 that were identified retrospectively from their institutional database. Hematoxylin and eosin–stained slides and paraffin blocks were screened for adequate tissue (at least enough for a 1-mm punch, with ≥50% tumor cellularity in the punched area).

Deparaffinization and RNA extraction were performed using RecoverALL Total Nucleic Acid Isolation Kit for FFPE (Thermo Fisher Scientific, Waltham, MA). Quality of RNA and input amount were determined by Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), with DV200 values, per TruSight RNA Fusion Panel kit protocol (Illumina, San Diego, CA, USA). Library preparation was performed using the TruSight RNA Fusion Panel kit. Sequencing was performed on the Illumina MiSeq and NextSeq 550 systems, using paired-end (2 × 75 nucleotides) reads.

The team reported that a total of 138 cases were successfully sequenced with adequate quality control metrics (90%). There were 110 sarcomas, with 31 sarcomas not otherwise specified, 25 Ewing sarcomas, and 13 synovial sarcomas, among others. A total of 101 of 138 (73%) cases were concordant by RNA sequencing and the prior test method. RNA sequencing identified an additional 30 cases (22%) with fusions that were not detected by conventional methods. In seven cases (5%), the additional fusion information provided by RNA sequencing would have altered diagnosis and management. A total of 19 (14%) novel fusion pairs, not previously described in the literature, were discovered.

The authors concluded that fusion analysis is a beneficial ancillary test that provides significant clinical value to the pathologist and treatment team. Targeted RNA sequencing on FFPE tissue is one method that enables the sensitive detection of multiple potential fusion genes simultaneously. This test could be performed at the time of pathologic examination in biopsy or resection specimens to aid in accurate diagnosis and clinical management. The study was published on December 1, 2021 in the Journal of Molecular Diagnostics.

Related Links:
Washington University School of Medicine
Thermo Fisher Scientific
Agilent Technologies
Illumina


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.